Vitrakvi set to become EU’s first tissue-agnostic cancer drug

EMA's CHMP delivered its first positive recommendation for a tissue-agnostic cancer therapy to Vitrakvi in its monthly basket of positive opinions, which also included one for GW’s Epidyolex.

CHMP backed approval of an MAA from Bayer AG (Xetra:BAYN) for Vitrakvi larotrectinib to treat

Read the full 425 word article

How to gain access

Continue reading with a
two-week free trial.